Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia
Background: Ranibizumab and aflibercept are approved in Italy for the anti-VEGF (vascular-endothelial-growth-factor) treatment of four retinal diseases: neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and retinal vein occl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-08-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | https://doi.org/10.1177/2284240318793905 |